ABSTRACT BACKGROUND: Lung cancer is the leading cause of cancer mortality in most countries, with every year's increasing incidence. At present, surgical resection of early stage disease presents the only treatment associated with a high likelihood of 5-year survival. On the other hand, patients with advanced disease have 5-year survival less than 5%. This poor prognosis is attributable largely to lack of efficient diagnostic methods for early detection and the inability to cure metastatic disease. Therefore, efforts aimed at early identification and interventions in lung cancer are of the highest importance. Mutations in ras oncogenes appear to play a significant role in the development of non-small cell lung carcinoma (NSCLC). Thus, the aim of our study was to determine the incidence of H-ras and K-ras mutations in patients with NSCLC of different histological subtypes: adenocarcinomas (AC), squamous cell carcinomas (SCC), large cell carcinomas (LCC), and adeno-squamous carcinomas (AC-SCC). METHODS: We analyzed 41 patients with stage I, II and III of histologically confirmed NSCLC (histological grade 2 and 3). DNA was isolated from frozen tumors by standard phenol-chloroform extraction. Mutations in exon 1 H-ras and K-ras gene were detected by PCR-SSCP method. RESULTS: Mutations in the H-ras gene were found in only 2 of 41 analyzed tumors (4.9%). The both mutations were found in SCC making the overall incidence in this histological subtype 10.5% (2 of 19). K-ras mutations were detected in 31.7% (13 out of 41) of tumors, with higher incidence in tumors of clinical stage I -45% (9 out of 20). CONCLUSION: Our results indicate that H-ras mutations apparently play an inferior role in lung carcinogenesis. However, mutations in K-ras gene probably present an early event in genesis of NSCLC, and not only in adenocarcinomas, as the majority of previous reports indicate, but also in squamous cell carcinomas as well.
INTRODUCTION
L ung cancer is one of the leading causes of cancer-related deaths in the world, causing over 1 million deaths worldwide each year (1) . Despite advances in clinical management, mortality and incidence have shown similar increasing trends over the last two decades. Only 13% of patients diagnosed with lung cancer survive 5 years which emphasis the need for improved therapeutic interventions (2) . The therapy of non-small cell lung carcinoma (NSCLC) which accounts for ~75-80% of all lung cancer cases, remains a clinical challenge. Radical treatment still gives the best results, but it depends primarily on early detection, since patients with advanced and metastatic disease have 5-year survival rates less than 5% (3) . The poor survival following lung cancer may be ascribed to its biological aggressiveness and a relative lack of symptoms attributable to early disease, combined with the rather poor sensitivity of the classical approaches for early detection (4) . Thus, the identification of early molecular events in lung carcinogenesis could have a major impact on early detection of this disease (5) . Proto-oncogenes of ras family (H-ras, K-ras and N-ras) encode for 21 kD proteins, which are located on the inner surface of the membrane where they act as signal transducers. Ras proteins normally respond to growth stimuli, such as epidermal and platelet-derived growth factors by exchanging guanosine triphosphate (GTP) for constitutively bound guanosine diphosphate (GDP) thereby triggering cell division. The signal is terminated when the Ras protein hydrolyzes its bound GTP to GDP in a reaction that is stimulated by a guanosine triphosphatase (GTPase) activating protein (GAP) (6) .
Hyperexpression of ras genes results in growth stimulation, whereas point mutations at codons 12, 13 and 61 alter their structure. This prevents inactivation, which results in inappropriate prolonged signaling for continued cell division, which ultimately leading to cell transformation (7) . The frequency of ras mutations in human cancers depends on the organ of origin, being rare in squamous cell carcinomas and adenocarcinomas of the breast, stomach and ovary and occurring in 30% to 50% of adenocarcinomas of the lung and the colon and almost all pancreatic cancers (8) . Mutations in colon and pancreatic cancers are found only in the K-ras gene. In cancers of the urinary tract and bladder, mutations are primarily in the H-ras gene and mutations in N-ras gene are found in leukemia. Thyroid carcinomas are unique in having mutations in all three ras genes (9) . Unlike H-ras gene, the incidence and prognostic significance of K-ras mutations in lung cancer have been largely studied. These mutations occur primarily in codon 12 and are found more often in adenocarcinomas obtained from smokers than nonsmokers. Besides that, a number of studies have suggested that such mutations represent a possible biomarker of poor survival, particularly in early stage disease (10) . This finding, however, is not universal and demands further investigations. The aim of our study was to determine the incidence of H-ras and K-ras mutations in patients with NSCLC, who undergone a surgical resection. We also correlated the incidence of ras gene mutations with prognostic feature -stage of disease, together with histological subtype and grade of tumors as indices further describing prognosis of NSCLC patients.
PATIENTS AND METHODS

Patients
Fresh tumor samples were obtained from 41 patients with histologically confirmed NSCLC. (Table 1) .
Tumor tissue was frozen in liquid nitrogen and stored at -80ûC until DNA extraction.
Genomic DNA was isolated by conventional proteinase K digestion followed by phenol/chloroform extraction and ethanol precipitation (12) and was finally dissolved in 100ml of sterile distilled water.
PCR-SSCP analysis
DNA fragments covering the coding regions of exon I H-ras and K-ras genes were amplified by PCR, using specific oligonucleotide primers for both genes. PCR reactions were designed to generate fragments 123 bp and 111 bp in length. The sequences of primers used for PCR amplification of exon I H-ras and K-ras genes were as follows: H-ras, sense:
5' -ATG ACG GAA TAT AAG CTG GT -3' (123 bp) H-ras, antisense:
5' -CGC CAG GCT CAC CTC TAT A -3' K-ras, sense:
5' -ATG ACT GAA TAT AAA CTT GT -3' (111 bp) K-ras, antisense:
5' -CTC TAT TGT TGG ATC ATA TT -3'
For PCR amplification exon I of both genes was used an optimized PCR protocol. We optimized PCR conditions according to Taq polymerase, amounts of primers, magnesium concentrations and cycling parameters to obtain efficient amplification of DNA with little or no background. We varied the amount of polymerase from 1 to 2.5 units; primers amounts for final concentration ranging from 0.2 mM to 0.8 mM and MgCl 2 concentrations were varied in a range of 1.5 to 2.5 mM (data not shown). The following conditions were found to provide the best sensitivity and specificity: DNA (500 ng) was amplified in 50 ml volumes in a reaction containing 0.6 mM of each primer, 0.2 mM dNTP mix, 10 mM Tris-HCl buffer (pH 8.4), 2.0 mM MgCl 2 and 1.5 U of Taq polymerase. PCR was carried out by initial denaturation at 95ûC for 5 minutes, followed by 35 amplification cycles of 950C (60 seconds) for denaturation, 58ûC (H-ras) or 51ûC (K-ras) (60 seconds) for annealing, 72ûC (60 seconds) for extension, followed by 10 minutes extension at 72ûC.
Mutated ras genes were identified using single strand conformation polymorphism (SSCP)
analysis. We used this method because it is rapid, well controlled and reproducible and, according to some researchers, more sensitive in detecting mutations than sequencing (13) . We used optimized electrophoretic conditions for exon I of H-ras and K-ras genes:
200V at 4ûC for 2 hours.
Statistical analysis
The differences in the incidence of ras mutations among tumor type, tumor grade and TMN value were calculated by the c 2 test.
RESULTS
The purpose of our investigation was to evaluate mutation status of two members of ras gene family (H-ras and K-ras) in non-small cell lung carcinoma of 41 patients who underwent a surgical resection. The obtained results are summarized in Table 2 .
Status of H-ras gene
Mutations in codon 12, 13 H-ras gene were detected by SSCP method ( Figure 1 ) in 2 of 41 analyzed tumors and, since both mutations were detected in squamous cell carcinoma, the incidence of H-ras mutations in this histological type of NSCLC is 10.5% (2 of 19). One mutation was detected in SCC stage I (1 of 12) and the other one in SCC stage II (1 of 2) (Figure 2) . One H-ras mutation was found in carcinoma of histological grade G2 (1 of 19) and one mutation was found in carcinoma of histological grade G3 (1 of 22) (Figure 3 ). 
DISCUSSION
A number of published data showed that mutations in oncogenes of ras family represent one of the most frequent abnormalities of dominant oncogenes in human tumors. These mutations were detected in about 30% of all human cancers and in all cases they were found in codons 12, 13 and 61 (14) . The consequence of such mutations is synthesis of structurally and functionally changed Ras protein.
Activation of ras is thought to represent only one step in the 'genetic cascade' of events leading to malignant transformation. In vitro work demonstrates that transfection of an activated ras gene can transform normal mouse fibroblasts (15) . In human tumors, frequency . PCR-SSCP analysis of exon I K-ras gene using 10% polyacrylamide gel stained with silver nitrate. Extra bands are seen in Lanes 2,3, 4, 5, 7 and 8; Lane 10, sample from peripheral blood leukocytes as a control Figure 3 . The incidence of H-ras mutations found in NSCLC of different histological grades Figure 6 . The incidence of K-ras mutations found in different histological subtypes of NSCLC Figure 7 . The incidence of K-ras mutations found inNSCLC of different histological grades. * indicates statistically significant difference of mutation incidence found in grades G2 and G3 carcinomas of found activated ras genes is dependent on tissue and tumor type. gives an early metastasis. Although in the group we studied there were more patients with SCC than with AC, we can conclude that mutations in K-ras gene appear early in genesis of AC because 50% of analyzed AC stage I harbor mutation in this gene.
In most studies published so far, SCC harbored ras mutations only exceptionally, in less than 5% of cases (23) . It has been thought that even when K-ras mutations occur as an early event during the development of the SCC, it probably does not confer a growth advantage to cells, at least in a subset of mutated tumors. Graziano found K-ras mutations in Our results are consistent with the most recent data showing that over 80% of all mutations in ras genes are found in K-ras. Beside that, over 80% of mutations in this gene are detected in codon 12, which seems to be more affected by cancerogenic agents from cigarette smoke (27) . All epidemiological studies confirmed that tobacco smoke, a complex mixture containing many carcinogens, is a major etiological agent of lung cancer, but we cannot discuss that because all patients included in our study were smokers or former smokers.
The development of NSCLC is a multistep process involving accumulation of genetic and epigenetic alterations of malignant cells. A number of literature data has showed that an oncogene activation of K-ras appears early in the process of lung carcinogenesis, but the exact time of its activation has not yet been estimated. We detected K-ras mutations in 45%
of NSCLC stage I and the found incidence was significantly lower in analyzed carcinomas G3 grade than in G2 grade. Based on these findings, we could make conclusion that the oncogene activation of K-ras is an early but not an initial event in the genesis of NSCLC.
Since the genetic instability is the characteristic of the malignant cell, every tumor represent The prognostic significance of K-ras mutations in NSCLC has also been studied in a number of retrospective series. In some of them, the presence of K-ras mutations has been found to be a negative prognostic factor, associated with early relapse and shortened survival (8) . However, this finding needs to be confirmed in studies that will provide a clearer understanding of the clinical relevance of this gene and suggest avenues for future research.
CONCLUSION
Our results indicate that H-ras mutations apparently play an inferior role in lung carcinogenesis. However, mutations in K-ras gene probably present an early event in genesis of NSCLC, and not only in adenocarcinomas, as the majority of previous reports indicate, but also in squamous cell carcinomas as well.
